Literature DB >> 35662004

Treatment approach to connective tissue disease-associated interstitial lung disease.

Timothy M Wilson1, Joshua J Solomon2, M Kristen Demoruelle3.   

Abstract

Interstitial lung disease (ILD) is a common manifestation in connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myositis (IM). ILD is associated with significant morbidity and mortality in nearly all CTD highlighting the critical need for effective treatment strategies in this patient population. In this review, we will summarize the approach to treatment when there is concern for CTD-ILD and highlight recent advancements in therapeutics within various forms of CTD-ILD.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35662004      PMCID: PMC9308694          DOI: 10.1016/j.coph.2022.102245

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   4.768


  50 in total

1.  Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.

Authors:  Shinji Sato; Masataka Kuwana; Takashi Fujita; Yasuo Suzuki
Journal:  Mod Rheumatol       Date:  2012-05-29       Impact factor: 3.023

2.  Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Zhiwei Chen; Xiaodong Wang; Shuang Ye
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 91.245

3.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

Review 4.  Connective tissue disease-associated lung disease.

Authors:  Amy L Olson; Kevin K Brown; Aryeh Fischer
Journal:  Immunol Allergy Clin North Am       Date:  2012-11       Impact factor: 3.479

5.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

6.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

Authors:  Athol U Wells; Kevin R Flaherty; Kevin K Brown; Yoshikazu Inoue; Anand Devaraj; Luca Richeldi; Teng Moua; Bruno Crestani; Wim A Wuyts; Susanne Stowasser; Manuel Quaresma; Rainer-Georg Goeldner; Rozsa Schlenker-Herceg; Martin Kolb
Journal:  Lancet Respir Med       Date:  2020-03-05       Impact factor: 30.700

7.  Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease.

Authors:  F Romero-Bueno; P Diaz Del Campo; E Trallero-Araguás; J C Ruiz-Rodríguez; I Castellvi; M J Rodriguez-Nieto; M J Martínez-Becerra; O Sanchez-Pernaute; I Pinal-Fernandez; X Solanich; T Gono; M A Gonzalez-Gay; M N Plana; A Selva-O'Callaghan
Journal:  Semin Arthritis Rheum       Date:  2020-06-01       Impact factor: 5.532

Review 8.  Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

Authors:  Esther F Vicente-Rabaneda; Belén Atienza-Mateo; Ricardo Blanco; Lorenzo Cavagna; Julio Ancochea; Santos Castañeda; Miguel Á González-Gay
Journal:  Autoimmun Rev       Date:  2021-04-19       Impact factor: 9.754

9.  Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the MUC5B Promoter Variant.

Authors:  Scott M Matson; Kevin D Deane; Anna L Peljto; Tami J Bang; Peter B Sachs; Avram D Walts; Christopher Collora; Shuyu Ye; M Kristen Demoruelle; Stephen M Humphries; David A Schwartz; Joyce S Lee
Journal:  Am J Respir Crit Care Med       Date:  2022-02-15       Impact factor: 30.528

10.  Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study.

Authors:  Natalia Mena-Vázquez; Marta Rojas-Gimenez; Carmen María Romero-Barco; Sara Manrique-Arija; Espildora Francisco; María Carmen Aguilar-Hurtado; Isabel Añón-Oñate; Lorena Pérez-Albaladejo; Rafaela Ortega-Castro; Francisco Javier Godoy-Navarrete; Inmaculada Ureña-Garnica; Maria Luisa Velloso-Feijoo; Rocio Redondo-Rodriguez; Francisco Gabriel Jimenez-Núñez; Blanca Panero Lamothe; María Isabel Padin-Martín; Antonio Fernández-Nebro
Journal:  J Clin Med       Date:  2021-02-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.